Abstracts Archive - Page 2011 of 2607 - ACR Meeting Abstracts

Abstract Number: 2104 • 2015 ACR/ARHP Annual Meeting
Influence on Treatment Decision Making of Providing Numerical Ranges of Side-Effect Risks
Nick Bansback^1,2, Mark Harrison³, William G Dixon⁴ and Paul Han⁵, ¹Centre for Health Evaluation and Outcome Sciences, Vancouver, BC, Canada, ²School of Population and Public Health, University of British Columbia, Vancouver, BC, Canada, ³Centre for Health Evaluation and Outcomes Sciences, St Paul's Hospital, Vancouver, BC, Canada, ⁴Manchester Academic Health Sciences Centre, Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, ⁵Center for Outcomes Research and Evaluation, Maine Medical Center, Portland, ME
Background/Purpose: Doctors and patients make treatment decisions after weighing benefits and harms. For harms, while people prefer treatments with smaller risks, how they react to…
Abstract Number: 2105 • 2015 ACR/ARHP Annual Meeting
Drug Survival and Cost Effectiveness in Patients on Reduced Dose Anti-TNF: Results of a 4 Year Prospective Observational Study
John Stack¹, Claire-Louise Murphy², Clara Bannon¹, Eithne Murphy¹, Trevor Duffy¹ and Maurice Barry¹, ¹Rheumatology, Connolly Hospital Blanchardstown, Dublin, Ireland, ²Rheumatology, Connolly Hospital Blanchardstow, Dublin, Ireland
Background/Purpose: Anti-TNF-α drugs are effective treatments for patients with inflammatory arthritis (IA). They are however expensive and their use carries a significant cost burden to…
Abstract Number: 2106 • 2015 ACR/ARHP Annual Meeting
Intensification to Triple Therapy Non-Biologic Disease-Modifying Antirheumatic Drugs for Rheumatoid Arthritis in the United States from 2009 to 2014
Jeffrey A. Sparks¹, Alexis A. Krumme², Olga S. Matlin³, Gregory Brill², William H. Shrank³, Niteesh K. Choudhry² and Daniel H. Solomon^2,4, ¹Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ³CVS Caremark, Woonsocket, RI, ⁴Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Several trials suggest that triple therapy with non-biologic disease-modifying antirheumatic drugs (ttDMARD) has similar efficacy compared to biologic DMARDs (bDMARD) for patients with RA.…
Abstract Number: 2107 • 2015 ACR/ARHP Annual Meeting
Initiation of Combination Triple Therapy in Real World Clinical Practice Rarely Replicates the Protocols Used in Randomized Controlled Trials.
Grant W. Cannon¹, Chia-Chen Teng², Ted R. Mikuls³, Jeffrey R. Curtis⁴, Derek Tang⁵, Bradley S. Stolshek⁵ and Brian Sauer⁶, ¹Division of Rheumatology, Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, ²HSR&D SLC VA Medical Center and University of Utah, Salt Lake City, UT, ³Veteran Affairs Nebraska-Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, NE, ⁴University of Alabama at Birmingham, Birmingham, AL, ⁵Amgen, Inc., Thousand Oaks, CA, ⁶Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT
Background/Purpose: Combination therapy with methotrexate (MTX), sulfasalazine (SUL), and hydroxychloroquine (HCQ) [triple therapy] is an effective treatment for rheumatoid arthritis (RA). Randomized controlled trials…
Abstract Number: 2108 • 2015 ACR/ARHP Annual Meeting
A Pragmatic Cluster-Randomized Controlled Trial of an Automated, Pharmacy-Based Intervention to Optimize Allopurinol Therapy in Gout
Ted R. Mikuls¹, T C Cheetham², Nazia Rashid², Gerald D. Levy³, Artak Kerimian⁴, KJ Low², Brian Coburn⁵, David T. Redden⁶, S. Louis Bridges Jr.⁷, Kenneth G. Saag⁶ and Jeffrey R. Curtis⁷, ¹Medicine, University of Nebraska Medical Center, Omaha, NE, ²Pharmacy Analytical Services, Kaiser Permanente Southern California, Downey, CA, ³Rheumatology, Kaiser Permanente Southern California, Downey, CA, ⁴Ambulatory Care Pharmacy, Kaiser Permanente Southern California, Downey, CA, ⁵Internal Medicine - Rheumatology, University of Nebraska Medical Center, Omaha, NE, ⁶University of Alabama at Birmingham, Birmingham, AL, ⁷Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Gout is a common form of inflammatory arthritis, often treated with allopurinol as a first-line urate lowering therapy. We have designed a large…
Abstract Number: 2109 • 2015 ACR/ARHP Annual Meeting
Racial Disparities in the Risk of Hospitalized Severe Allopurinol Hypersensitivity Syndrome – a US Nationwide Study (2009-2011)
Na Lu¹, Sharan K. Rai², Jeewoong Choi³ and Hyon K. Choi¹, ¹Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ²Experimental Medicine, University of British Columbia, Vancouver, BC, Canada, ³Massachusetts College of Pharmacy and Health Sciences, Boston, MA
Background/Purpose: Allopurinol is the leading choice of urate-lowering therapy for gout (>95% of treated cases); however, it is associated with the rare but potentially fatal…
Abstract Number: 2110 • 2015 ACR/ARHP Annual Meeting
Imaging and Safety Assessments Following Treatment with Febuxostat and Placebo for 2 Years in Subjects with Early Gout
Nicola Dalbeth¹, Kenneth G. Saag², William Palmer³, Hyon Choi³, Barbara Hunt⁴, Patricia MacDonald⁴, Ulrich Thienel⁴ and Lhanoo Gunawardhana⁴, ¹Department of Medicine, University of Auckland, Auckland, New Zealand, ²Div Clinical Immun & Rheum, University of Alabama at Birmingham, Birmingham, AL, ³Massachusetts General Hospital/Harvard Medical School, Boston, MA, ⁴Takeda Pharmaceuticals International, Deerfield, IL
Background/Purpose: No clinical trials had previously investigated the characteristics of joint damage in early gout or the benefit of instituting urate-lowering therapy (ULT) earlier in…
Abstract Number: 2111 • 2015 ACR/ARHP Annual Meeting
A Study to Evaluate the Efficacy and Safety of Arhalofenate for Preventing Flares and Reducing Serum Uric Acid in Gout Patients
Alexandra Steinberg¹, Harinder Chera¹, Yun-Jung Choi¹, Robert Martin¹, Charles McWherter¹, Yunbin Zhang², Pol Boudes¹ and on behalf of the Arhalofenate Anti-Flare Therapy Study Group, ¹Cymabay Therapeutics, Newark, CA, ²INC Research, Raleigh, NC
Background/Purpose: Arhalofenate is a novel Urate-Lowering Anti-Flare Therapy (ULAFT) to treat gout. It lowers serum uric acid (sUA) by blocking URAT1, a tubular UA transporter, and…
Abstract Number: 2112 • 2015 ACR/ARHP Annual Meeting
Analysis of Gout Subjects Receiving Lesinurad and Allopurinol Combination Therapy By Baseline Renal Function
Kenneth G. Saag¹, Thomas Bardin², Alexander So^3,4, Puja Khanna⁵, Chris Storgard⁶, Scott Baumgartner⁷, Maple Fung⁷, Nihar Bhakta⁷, Scott Adler⁸, Jeff Kopicko⁷ and Michael A. Becker⁹, ¹University of Alabama at Birmingham, Birmingham, AL, ²Lariboisière Hospital, Paris, France, ³Rheumatology, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Lausanne, Switzerland, ⁴CHU Vaudois, University of Lausanne, Lausanne, Switzerland, ⁵Division of Rheumatology/Dept. of Internal Medicine, University of Michigan Medical Center, Ann Arbor, MI, ⁶4939 Directors Place, Ardea Biosciences, Inc., San Diego, CA, ⁷Ardea Biosciences, Inc., San Diego, CA, ⁸AstraZeneca Pharmaceuticals, Wilmington, DE, ⁹University of Chicago, Chicago, IL
Background/Purpose: Two randomized, double-blind, placebo-controlled Phase III clinical trials showed that lesinurad (200 or 400 mg) when added to allopurinol (200-900 mg) significantly increased the…
Abstract Number: 2113 • 2015 ACR/ARHP Annual Meeting
Lesinurad, a Novel Selective Uric Acid Reabsorption Inhibitor, in Combination with Febuxostat, in Patients with Tophaceous Gout
Nicola Dalbeth¹, Graeme Jones², Robert Terkeltaub³, Dinesh Khanna⁴, Jeff Kopicko⁵, Nihar Bhakta⁵, Maple Fung⁵, Chris Storgard⁶, Scott Baumgartner⁵ and Fernando Perez-Ruiz⁷, ¹Department of Medicine, University of Auckland, Auckland, New Zealand, ²Musculoskeletal Unit, Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia, ³Medicine-Rheumatology, University of California, San Diego, La Jolla, CA, ⁴Div of Rheumatology, University of Michigan, Ann Arbor, MI, ⁵Ardea Biosciences, Inc., San Diego, CA, ⁶4939 Directors Place, Ardea Biosciences, Inc., San Diego, CA, ⁷Servicio de Reumatologia, Hospital Universitario Cruces, Baracaldo, Spain
Background/Purpose: Lesinurad (LESU; RDEA594) is a selective uric acid reabsorption inhibitor (SURI) being investigated for the treatment of gout in combination with a xanthine oxidase…
Abstract Number: 2114 • 2015 ACR/ARHP Annual Meeting
Higher Total Knee Arthroplasty Revision Rates in Black Americans: A Systematic Literature Review and Meta-Analysis
Anne R. Bass¹, Kelly McHugh¹, Kara Fields^2,3, Rie Smethurst⁴, Michael Parks⁵ and Susan M. Goodman¹, ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²Medicine/Rheumatology, Hospital for Special Surgery, New York, NY, ³Biostatistics, Hospital for Special Surgery, New York, NY, ⁴Education - Academic Training, Hospital for Special Surgery, New York, NY, ⁵Orthopedics, Hospital for Special Surgery, New York, NY
Background/Purpose: Utilization of total knee arthroplasty (TKA) is lower among blacks than whites in the United States (U.S.), which may be due to blacks' perception…
Abstract Number: 2115 • 2015 ACR/ARHP Annual Meeting
Intra-Operative Synovitis Predicts Worse Pain and Function 2 Years after Total Knee Arthroplasty for Osteoarthritis
Lisa Mandl¹, Shivi Duggal², Kelly McHugh³, Xian Wu⁴, Geoffrey H. Westrich², Thomas Sculco², John A. Carrino⁵, Edward F. DiCarlo⁶, Steven R. Goldring¹ and Charles Cornell², ¹Hospital for Special Surgery, New York, NY, ²Orthopedics, Hospital for Special Surgery, New York, NY, ³Rheumatology, Hospital for Special Surgery, New York, NY, ⁴Biostatistics and Epidemiology, Weill Cornell Medical College, New York, NY, ⁵Department of Radiology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁶Laboratory Medicine, Hospital for Special Surgery, New York, NY
Intra-Operative Synovitis Predicts Worse Pain and Function 2 Years After Total Knee Arthroplasty for Osteoarthritis Background/Purpose: Total knee arthroplasty (TKA) is one of the most common…
Abstract Number: 2116 • 2015 ACR/ARHP Annual Meeting
Advice to Remain Active While Awaiting Physiotherapy Is Associated with Superior Long-Term Outcome Among Patients with Distal Arm Pain – Results from a Randomised Controlled Trial
Gareth T Jones^1,2, Gary J. Macfarlane^1,2, Keith Palmer^3,4, David Coggon^3,4, Karen Walker-Bone^3,4, Kim Burton⁵, Peter Heine⁶, Candida McCabe^7,8, Paul McNamee⁹ and Alex McConnachie¹⁰, ¹Musculoskeletal Research Collaboration (Epidemiology Group), University of Aberdeen, Aberdeen, United Kingdom, ²University of Aberdeen, Arthritis Research UK / MRC Centre for Musculoskeletal Health and Work, Aberdeen, United Kingdom, ³MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, United Kingdom, ⁴University of Southampton, Arthritis Research UK / MRC Centre for Musculoskeletal Health and Work, Southampton, United Kingdom, ⁵Centre for Applied Psychological and Health Research, University of Huddersfield, Huddersfield, United Kingdom, ⁶Warwick Clinical Trials Unit, University of Warwick, Coventry, United Kingdom, ⁷Nursing and Midwifery, University of the West of England, Bristol, United Kingdom, ⁸Royal United Hospital NHS Foundation Trust, Bath, United Kingdom, ⁹Health Economics Research Unit, University of Aberdeen, Aberdeen, United Kingdom, ¹⁰Robertson Centre for Biostatistics, University of Glasgow, Glasgow, United Kingdom
Background/Purpose: Pain in the distal upper limb (elbow, forearm, wrist or hand) is common, yet the best approach to management is unclear. While the etiological…
Abstract Number: 2117 • 2015 ACR/ARHP Annual Meeting
Weight Predicts Back Pain in Young Adult Women, Independent of Physical Activity: Data from the Australian Longitudinal Study on Women’s Health
Sharmayne Brady¹, Sultana Monira Hussain², Wendy Brown³, Stephane Heritier¹, Baki Billah¹, Yuanyuan Wang⁴, Helena Teede^5,6, Donna Urquhart¹ and Flavia Cicutinni¹, ¹Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia, ²Department of Epidemiology and Preventive Medicine,, School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia, ³Faculty of Health and Behavioural Sciences, School of Human Movement Studies, University of Queensland, Brisbane, Australia, ⁴Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia, ⁵School of Public Health and Preventive Medicine, Department of Epidemiology and Preventive Medicine, Monash Centre for Health Research and Implementation, Monash University, Melbourne, Australia, ⁶Diabetes and Endocrine Unit, Monash Health, Melbourne, Australia
Background/Purpose: Low back pain (LBP) causes enormous financial and disability burden worldwide, and therapeutic options have limited efficacy. This burden could be potentially reduced by…
Abstract Number: 2118 • 2015 ACR/ARHP Annual Meeting
Prescription Medication Use in Community-Based US Adults with Chronic Low Back Pain: Nhanes 2009-2010
Anna Shmagel¹ and Robert Foley², ¹Rheumatic & Autoimmune Diseases, University of Minnesota Medical School, Minneapolis, MN, ²Renal Diseases and Hypertension, University of Minnesota, Minneapolis, MN
Background/Purpose: Chronic low back pain (cLBP) is a significant public health problem. Establishing treatment guidelines has been difficult due to heterogeneity of research data. Little…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].